PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.89%
Both companies show declining cash positions (-7.89% vs AGEN's -16.82%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.89%
Below half of AGEN's -16.82%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.62%
Below half of AGEN's -15.81%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-4.83%
Below half AGEN's 9.86%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.38%
Below half of AGEN's 1.44%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
0.5-0.75x AGEN's -11.16%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-25.56%
Less than half of AGEN's 99.88%. David Dodd sees a more disciplined AP approach or lower volume.
-49.71%
Higher Short-Term Debt Growth compared to AGEN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
240.62%
Below half of AGEN's -16.71%. Michael Burry suspects a big gap in pre-sales traction.
-18.75%
Exceeding 1.5x AGEN's -4.91%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-24.27%
Less than half of AGEN's 5.77%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.27%
Less than half of AGEN's 1.64%. David Dodd sees far fewer liability expansions relative to competitor.
5.27%
Above 1.5x AGEN's 0.45%. Michael Burry suspects heavy new equity expansion or dilution.
-5.68%
≥ 1.5x AGEN's -3.39%. David Dodd sees higher yoy retained profits than competitor.
-17.53%
Above 1.5x AGEN's -9.48%. Michael Burry sees a significant jump in intangible or market-based gains. Scrutinize risk of reversal.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half AGEN's -62.03%. Michael Burry sees potential underperformance in building shareholder capital.
-7.59%
0.5-0.75x AGEN's -11.16%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
-49.71%
Less than half of AGEN's 3.35%. David Dodd sees less overall debt expansion vs. competitor.
7.55%
Less than half of AGEN's 96.58%. David Dodd sees better deleveraging or stronger cash buildup than competitor.